Introduction
E�������� ��r��b�c������� (ET) �� ��� ���� c����� ��b��p� �� c�����c P�������p��� c�r������� ��g���v� b��� ��rr�� proliferation tumor (MPN). Bone marrow fibrosis, thrombus ��� r��k �� b������g �r� ��� ���� c����� c��p��c������ of ET. Approximately 10% of patients have acute leukemia �r�����r������ (1) . I� r�c��� ���r�, ��� ET r��� ��� b��� �� the increase annually, and approximately 5-8/10 million ����v������ ��r� ���g����� ���� ET �� 2005 (2) .
ET ��� b� ��� r����� �� c��b���� ����c�� �� g��� ��� environment. JAK2V617F mutations can occur in 50-60% of ET p�������, ��� ��� ��������-p�����v� p������� ��v� � ��g��r r��k �� ��r��b���b�����. R�v�r�� p�����v� �������� ������ ��� ��g���v��� c�rr������ ���� ��rv�v�� ���c���� ��� ��r���� ��v�r�� �v��� �cc�rr��c�, ��gg�����g ���� ��� JAK2V617F �������� p���� �� ��p�r���� r��� �� ��� p����g������ �� ET (3, 4) . However, 50% of patients show a JAK2V617F-negative state. Recently, gene sequencing identified that MPLW515L/K and CALR gene of mutations can compensate for the deficiency of JAK2V617F ��g���v���, ���c� c�� pr�v��� �� ��p�r���� b���� for explaining genetic pathogenesis mechanism of ET (5, 6) .
T�� ��� �� ��� pr����� ����� ��� �� ������� ��� �������� r��� �� JAK2V617F, MPLW515L/K ��� CALR g���� �� ����� p������� ���� ��������� ��r��b�c������� (ET) ��� ��� �cc�r�c� �� ��� c��b���� ����c���� b� ��� r�c��v�r �p�r����g c�rv�. The main steps are as follows: i) DNA extraction: a) 500 µl peripheral blood was extracted in a 2-ml EP tube. One milliliter of red blood cell lysis was added at 4˚C and centrifuged at 8,000 x g for 1 min; b) the supernatant was discarded and r������� ����� ���p �� ��� p�p� b����� ��� r�������. Pr������ (125 µl) was added with gentle mixing for 5 sec. Subsequently, the tube was placed in 65˚C water bath for 10 min and gently mixed every 2 min until the precipitation was completely dissolved; iii) 275 µl of protein clear solution was added with gentle mixing for 5 sec. It was followed by incubation at -20˚C for about 10 min and then centrifuged at 10,000 x g for 5 min; d) the supernatant was discarded, and 1 ml of 70% ethanol was added with gentle mixing for 5 sec. The tube contents were then centrifuged at 10,000 x g for 1 min; e) the ethanol ��� ���c�r���, ��� ��� DNA c��������g r�b� ��� p��c�� �� room temperature for 2 min for volatilization of extra alcohol. Subsequently, 100 µl DNA dissolving solution was added and then tube was incubated at 65˚C for 15 min to fully dissolve DNA; ��� �) DNA c��c���r����� ��� p�r��� ��r� �����r�� ���� UV �p�c�r�p��������r. ��) Pr���r ��q���c�� ��r� ����g��� ��r ��� ��r��r� pr���r� ��� � r�v�r�� ���v�r��� pr���r. PCR pr���c� ��� 203 bp ��� ��� r���r��c� ��� 364 bp. Pr���r� ��r� pr���c�� b� S���g��� B����g�c�� E�g����r��g C�., L��. (S���g���, C����). F�r��r� �p�c���c, 5'-AGCATTTGGTTTTAAATTATGGAGTAT ATT-3'; ��r��r� ����r���, 5'-ATCTATAGTCATGCTGAAA GTAGGAGAAAG-3' ��� r�v�r��, 5'-CTGAATAGTCCTACA GTGTTTTCAGTTTCA-3'. ���) PCR r��c����: 25 �g �� DNA (10 ����/�), 0.2 �� forward primer and 0.4 µl (10 mmol/l) reverse primer, 12.5 Master mix and double ionized water were added for final volume of 25 µl. PCR amplification cycle parameters were pre-denaturation at 95˚C for 4 min, denaturation at 95˚C for 30 sec, annealing at 55˚C for 30 sec, extension at 72˚C for 1 min, 35 cycles, final extension at 72˚C for 7 min. 1.5% �g�r��� g�� c��������g �������� br����� ��� pr�p�r�� ��r ��� ��������. F�v� ��cr�����r� �� PCR pr���c�� ��� 1X TBE buffer was mixed and added for electrophoresis at 90 V for 40 ���. T�� ���g� ��� ��k�� ��� �������� ���� UV p�r�p�c-��v� ���g� ����r�����. �v) G��� ��q���c��g: p�����v� �p�c����� ��r� r��r��v�� and purified after PCR amplification with the outside primers. Statistical analysis. SPSS 19.0 ��������c�� ������r� (C��c�g�, IL, USA) ��� ���� ��r ���� pr�c�����g. M����r����� ���� �r� pr������� �� ���� ± ������r� ��v������, ��� c��p�r���� b������ gr��p� �� ����� ����g �-����. C�����b�� ���� �r� pr������� �� p�rc����g�, c��p�r���� b������ ��� gr��p� ��r� ���� χ 2 test. The diagnostic sensitivity, specificity and accur�c� ��� �������� ����g ��� r�c��v�r �p�r����g c�rv� (ROC). P<0.05 indicates a statistically significant difference. There were 89 (57.79%) cases of JAK2V617F mutations in the ET group, 7 (4.55%) cases of MPL mutations and 48 (31.17%) cases of CALR mutations. CALR and JAK2V617F mutations at the same time were positive in 7 cases (4.55%) and negative in 24 cases (15.58%). JAK2V617F positive with 
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JAK �� � c���� �� ���-r�c�p��r ��r����� pr����� k�����. T�� g��� ��c����g JAK2 �� �� c�r������� 9 (9p24) ��� �� �� expressed in almost all tissues. The most obvious structure of JAK �� c��r�c��r���� �� ���� ��� C ��r����� ��� ��� ��c����� �� c�������c ��� N ��r����� ��� ��r�� c����rv�� ��r�c��r�� ��c�����. T�� ������ p�r� ��� ��� ��c�����. D�����r��� �� JAK ��g��� �� pr����� ��b-������ �� ��g��� �r�����c���� ��� �r���cr�p������ �c��v����� (STAT). JAK c�� b��� ���� ��� c����rv�� BOX1 ��� BOX2 �� c���k��� r�c�p��r ��� �������� the motif in the cytokine receptor juxtamembrane region. It �cc�r� �� � ��r��� �� p���p��r������� ����r ��� ����������� �� r�c�p��r� ��� ��g���� ��� ����c��v� �c��v��� ������r��� ��b��r���� STAT, ���c� �r�����c���� �� ��� ��c���� ��� b���� with the nuclear specific DNA regulatory elements so as to g���� �r���cr�p����, ���c� �� ��� JAK-STAT p������ (8) . T�� identification of JAK2V617F provides an important clue to explore the pathogenesis of ET.
MPL �� ��r��b�p������ r�c�p��r ��� ��� p�p���� ��q���c� ��� 633 ����� �c���. T�� ��p�� �� ������c c��� ��������� MPLW515L/K were confirmed to exist in 5 and 1% of patients with negative JAK2V617F bone marrow fibrosis (9 W� c��c����� ��r��g� ��� ����� ���� JAK2V617F ��� MPL ��������� �� ��� c���� �r��������, ��� CALR ��������� c�� ���� �� ��� c���g� �� �p�� r�����g. T�� JAK2V617F ��� CALR gene mutation rates in the ET group were significantly ��g��r ���� ����� �� ��� gr��p �� ��c����r� ��r��b�c�-themia and the positive MPL mutation rate was only 4.55%. MPL ����r p�����v� �������� r��� ��� b� r������ �� r�c��� ��c��r� (14) ��� ���p�� ����. T�� ����v����� �� ��� ����� �� ���� ��� ��r�� k���� �� g���� �� MPN ��� c�r���� p�����v� �������� r���� b���� �� � pr�v���� ����� (15) . G��� �������� ��r ���p�-����� ��rv�c� ���� ���p�� ��cr����� p�������� ����c���� ���� ��� CALR and JAK2V617F mutation can be a specific marker of ET �cr�����g. T�� ���r�c����g �� ��� ����� ��� ���� �� ��� ��� ��v��v� ����r ��p�� �� MPN, ���c� c����� c��p�r� ��� CALR ��� JAK2V617F �������� �� �����r��� ��p�� �� MPN. In addition, the study detected the relative expression levels of JAK2V617F ��� CALR ��r��g� q���������v� �������� ��� ��� p�����v� JAK2V617F, CALR �������� ����� ��� c��b������� �� ���g�����c cr���r�� r��p�c��v���, ������ ���� c��b���-���� ��� �� ����� ��� c�� ��pr�v� �bv������ ��� ���g�����c sensitivity, specificity and accuracy. It provides an important r���r��c� b���� ��r ��r�� c����c�� r�c�g������.
I� c��c������, ���� ��� ��cr����� JAK2V617F-��� CALR-p�����v� �������� r���, ��� c��b������� �� b��� c�� significantly improve the sensitivity, specificity and accuracy �� ��� ���g����� �� ET.
